Close

pCDCAR1 CAIX h(4γ), T (CAR-T-2-M305-4G)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CAIX chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CAIX. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CAIX antibody linked to CD4 transmembrane domain and FcεRIγ signaling domains. And the vector product was designed for the treatment of renal cell carcinoma (RCC).

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Carbonic anhydrase IX (CA9)
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Renal cell carcinoma (RCC)
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • 8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-CD4-FcεRIγ
  • Discription of Signaling Cassetes
  • CD4
    Cluster of Differentiation 4 (CD4) is a glycoprotein expressed on the surface of T helper cells, regulatory T cells, monocytes, macrophages and dendritic cells, and plays an important role in the development and activation of T cells. On T cells, CD4 is the co-receptor for the T cell receptor (TCR), and these two distinct structures recognize the Antigen-Major Histocompatibility Complex (MHC). CD4 signaling in CAR ensures specificity of the TCR-antigen interaction, prolongs the contact between the T cell and the antigen presenting cell and recruits the tyrosine kinase Lck, which is essential for T cell activation.
    FcεRIγ
    The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE). FcεRI is a key molecule involved in allergic reactions. It is a tetramer composed of 1alpha, 1 beta, and 2 gamma chains. The gamma chains are also subunits of other Fc receptors. The scFv-based CARs engineered to contain a signaling domain from FcεRIγ have been shown to deliver a potent signal for T cell activation and function.

Target

  • Clone
  • G250
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CA9
  • Synonyms
  • CA9; CAIX; MN; carbonic anhydrase 9

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
FACS

Fig.1 Fluorescence-activated cell sorting analysis.

CAR Construction : G250 scFv-41BB-CD28ζ Latest CAR Construction

Fig.1 Fluorescence-activated cell sorting analysis.

CAR-positive rate of lentivirus-transduced NK92 cells. NK92 cells were transduced with empty lentivirus vector (Ctrl-NK92) or lentivirus containing the CAIX-specific CAR encoding sequence (CAR-NK92) and were selected with puromycin.

Zhang, Q., Xu, J., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Wang, Z., Fu, Q., & Zheng, J. (2018). Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncology reports, 40(6), 3714–3724.

WB

Fig.2 Western blot analysis.

CAR Construction : G250 scFv-41BB-CD28ζ Latest CAR Construction

Fig.2 Western blot analysis.

Western blot analysis of the CAR expression in NK92 cells with a monoclonal anti-human CD3ζ antibody. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was also detected as an internal control.

Zhang, Q., Xu, J., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Wang, Z., Fu, Q., & Zheng, J. (2018). Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncology reports, 40(6), 3714–3724.

FuncS

Fig.3 Functional studies.

CAR Construction : G250 scFv-41BB-CD28ζ Latest CAR Construction

Fig.3 Functional studies.

Specific cytokine release of CAIX-specific CAR-NK92 cells against CAIX+ cells.

Zhang, Q., Xu, J., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Wang, Z., Fu, Q., & Zheng, J. (2018). Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncology reports, 40(6), 3714–3724.

Cyt

Fig.4 Cytotoxicity assay.

CAR Construction : G250 scFv-41BB-CD28ζ Latest CAR Construction

Fig.4 Cytotoxicity assay.

Specific cytotoxicity exhibited by CAIX-specific CAR-NK92 cells against CAIX+ target cells.

Zhang, Q., Xu, J., Ding, J., Liu, H., Li, H., Li, H., Lu, M., Miao, Y., Wang, Z., Fu, Q., & Zheng, J. (2018). Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma. Oncology reports, 40(6), 3714–3724.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CAIX scFv h(CD4-FcεRIγ) CART, pCDCAR1 (CAR-T-2-M305-4G). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.